Surgery
Volume 146, Issue 2 , Pages 213-219 , August 2009

ERBB2 suppression decreases cell growth via apoptosis in gastrointestinal adenocarcinomas

,Accepted 6 April 2009.

References 

  1. Phillips C. Spotlight: the curious rise of esophageal adenocarcinoma. NCI Cancer Bulletin. 2008;Available from: http://www.cancer.gov/ncicancerbulletin/NCI_Cancer_Bulletin_051606/page4Accessed June 18, 2009
  2. PDQ® cancer information summaries: prevention. NCI Topics Page. National Cancer Institute Web site. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/esophageal/HealthProfessional/page2. Accessed on June 18, 2009.
  3. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–2053
  4. Metzger R, Schneider PM, Warnecke-Eberz U, et al. Molecular biology of esophageal cancer. Onkologie. 2004;27:200–206
  5. Lin J, Beer D. Molecular biology of upper gastrointestinal malignancies. Semin Oncol. 2004;31:476–486
  6. Dahlberg PS, Ferrin LF, Grindle SM, et al. Gene expression profiles in esophageal adenocarcinoma. Ann Thorac Surg. 2004;77:1008–1015
  7. Kuwano H, Kato H, Miyazaki T, et al. Genetic alterations in esophageal cancer. Surg Today. 2005;35:7–18
  8. Miller CT, Moy JR, Lin L, et al. Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin Cancer Res. 2003;9:4819–4825
  9. Jenkins GJ, Doak SH, Parry JM, et al. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br J Surg. 2002;89:824–837
  10. Chiang PW, Beer DG, Wei WL, et al. Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients. Clin Cancer Res. 1999;5:1381–1386
  11. Park JB, Rhim JS, Park SC, et al. Amplification, overexpression, and rearrangement of erbB-2 protooncogene in primary human stomach carcinomas. Cancer Res. 1989;49:6605–6609
  12. Tanner M, Hollmen M, Junttila TT, et al. Amplification of Her-2 in gastric carcinoma: association with topoisomerase II-α gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Onc. 2006;16:273–278
  13. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res. 2003;284:99–110
  14. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712
  15. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–145
  16. Arteaga CL, Baselga J. Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?. Cancer Cell. 2004;5:525–531
  17. Casimiro M, Rodriguez O, Pootrakul L, et al. ErB-2 induces the cyclin-D1 gene in prostate epithelial cells in vitro and in vivo. Cancer Res. 2007;67:4364–4372
  18. Safran H, Steinhoff M, Mangray S, et al. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol. 2001;24:496–499
  19. Hirsch FR, Franklin WA, Veve R, et al. HER2/neu expression in malignant lung tumors. Semin Oncol. 2002;2929(1 Suppl 4):51–58

 Presented at the 69th Annual Meeting of the Society of University Surgeons, Fort Myers, Florida, February 3–6, 2009.

 Supported in part by research grants from the National Institutes of Health (NIDDK R01 DK063615 and CA094084 to M.Y.).

PII: S0039-6060(09)00251-7

doi: 10.1016/j.surg.2009.04.008

Surgery
Volume 146, Issue 2 , Pages 213-219 , August 2009

Article Tools

* Image Usage & Resolution